Moleculin Biotech is a pre-revenue, late-stage pharmaceutical development company focused on advancing Annamycin (naxtarubicin), an experimental next-generation anthracycline chemotherapy, toward FDA approval. Existing anthracyclines treat roughly half of all cancers but cause significant cardiotoxicity and are susceptible to multidrug resistance, limiting their use. Moleculin argues Annamycin addresses both problems through a novel molecular structure and a lipid-based delivery system. The lead indication is relapsed/refractory AML (R/R AML), where Moleculin is running the pivotal global Phase 3 MIRACLE trial comparing Annamycin plus high-dose cytarabine against cytarabine plus placebo in second-line patients. A key interim data readout is expected in mid-2026, which management views as a catalyst to attract a large pharma partner or out-licensing deal. A secondary indication is soft tissue sarcoma with lung metastases, where a Phase 1B/2 trial showed encouraging results. Beyond Annamycin, Moleculin has two earlier-stage programs licensed from MD Anderson: WP1066, a STAT3 inhibitor being studied in glioblastoma and pediatric brain tumors (with an FDA Rare Pediatric Disease designation that could yield a Priority Review Voucher upon approval), and WP1122, a glycolysis inhibitor with limited active development. Moleculin funds operations through equity raises, outsources all manufacturing, and relies on investigator-initiated trials to advance its WP1066 and sarcoma programs with minimal cash outlay. The company's primary monetization path is either out-licensing Annamycin or building a contracted commercial function upon approval.